Ribociclib
Brand: Kisqali
Anticancer
CDK4/6 inhibitor
Pharmacokinetics
| Half-life | 32 hours |
| Tmax | 2 h |
| Bioavailability | 65 % (approx) |
| Protein Binding | 70 % |
| Volume of Distribution | 1.2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Causes QT prolongation risk; ECG & electrolytes monitoring recommended. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Neutropenia, hepatotoxicity, QT prolongation
Contraindications:
Baseline QTc >450 ms; uncontrolled arrhythmia
Precautions:
ECG + electrolytes monitoring recommended regularly